Hypocalcemia is most commonly seen within the first six months of GLP-1 receptor agonist therapy, while hypercalcemia is noted to occur after at least six months of therapy
GLP-1 receptor agonists are prescribed to manage type 2 diabetes by regulating blood sugar and, in some cases, to support weight loss
While GLP-1 medications hold immense appeal and transformative potential, it's essential to understand that their efficacy is maximized when combined with a healthy diet, regular exercise, and other lifestyle modifications
Mineral and vitamin deficiencies on a GLP-1 are common in individuals with obesity and diabetes, yet theyre often overlooked
Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy
December 22, 2025